. These AMPs have a broad range of activities against microorganisms and may be involved in the direct inactivation of viruses through membrane destabilization (Kamen & Tangpricha, 2010) Vitamin D insufficiency has been reported to be common in athletes in the United Kingdom (UK) especially when training in the winter months (Close et al., 2013; He et al., 2013; Morton et al., 2012) . Two studies that assessed the vitamin D status of UK-based professional athletes (latitude 53N) reported that 62% of athletes (38/61) including professional rugby players, soccer players and jockeys had inadequate serum total 25(OH)D concentrations (< 50 nmol/L) in the winter months (Close et al., 2013) and 65% of elite soccer players in the English Premier League (13/20) presented with serum total 25(OH)D concentrations <50 nmol/L in December (Morton et al., 2012) .In our previous study on a large student cohort of endurance athletes, we also found that 55% of endurance athletes (100/181) had serum total 25(OH)D concentrations <50 nmol/L at the end of the 4-month winter training period (He et al., 2013) . Given that the high prevalence of insufficient vitamin D status in athletes in the UK during winter months, it seems probable that vitamin D supplementation could be desirable for athletes during this period to increase vitamin D concentrations to up-regulate the expression of AMPs and possibly reduce the risk of respiratory infections.
The purpose of this study was to examine the effect of 14 weeks of vitamin D 3 supplementation (5000 IU/day) on the resting plasma cathelicidin concentration and the salivary concentrations and secretion rates of SIgA, cathelicidin, lactoferrin and lysozyme in a population of individuals engaged in regular sport training during a winter training period.
Methods

Participants
Fifty healthy men aged 20.4 ± 1.9 years who were engaged in regular sports training (such as rugby, volleyball, swimming, triathlon, cycling and racquet sports) from Loughborough University, UK (latitude 53N) volunteered to participate in the study during November 2013 and their self-reported training loads (determined by a pre-screening questionnaire) averaged 11 ± 4 h/week (mean ± SD). Participants were required to complete a comprehensive healthscreening questionnaire prior to starting the study and had not taken any regular medication or antibiotics in the 3 months prior to the study. All participants were fully informed about the rationale for the study and of all experimental procedures to be undertaken. Participants provided written consent to participate in the study, which had earlier received the approval of Loughborough University ethical advisory committee. Participants were enrolled after having fulfilled all inclusion criteria, and presenting none of the exclusion criteria (determined by questionnaire). Participants could be included if they were currently healthy (with no health problems or infection symptoms within the previous 2 weeks), engaged in regular sports training at least 3 sessions and at least 3 h of total moderate/high-intensity training time per week and were between 18-35 years of age. Participants representing one or more of the following criteria were excluded from participation: smoking or use of any medication, suffering from or had a history of cardiac, hepatic, renal, pulmonary, neurological, gastrointestinal, haematological or psychiatric illness. Participants were not allowed to take any other supplements, other than a daily multivitamin tablet providing no more than the Recommended Dietary Allowances of essential vitamins.
Study protocol
Information about the study was given to the participants 1-2 weeks before their first visit to the laboratory. For the first visit to the laboratory, participants arrived in the morning at 09:00-12:00 following a 3-h fast and their body mass and stature were recorded. Participants were required to abstain from any strenuous physical activity for 24 h before coming to the laboratory. Participants sat quietly for 10 min and completed a health-screening questionnaire and inclusion/exclusion criteria questionnaire before signing an informed consent form and providing an unstimulated saliva sample by passive dribble into a preweighed sterile collection tube for a timed period (usually 2 min; longer was allowed if the volume of saliva collected after 2 min was insufficient). After centrifugation for 2 min at 5000 g to remove cells and insoluble matter, saliva samples were stored frozen at -20ºC prior to analysis. Subsequently, a resting venous blood sample (6 ml) was obtained by venepuncture from an antecubital forearm vein into a vacutainer tube (Becton Dickinson, Oxford, UK) containing K 3 EDTA and haematological analysis was immediately carried out (including haemoglobin, haematocrit and total and differential leukocyte counts) using an EDTA plasma with 20X dilution was assayed in duplicate for cathelicidin concentration using a commercially available ELISA kit (Hycult Biotech, Uden, The Netherlands)
according to the manufacturers' instructions. The intra-assay CV was ±2.4% across a working range of 0.1-100 g/L.
Saliva analysis
Saliva samples were analysed in duplicate for the salivary AMPs. The saliva volume collected was estimated by weighing and the saliva flow rate was calculated. Saliva samples with 5X dilution were analysed for SIgA using an ELISA kit (Salimetrics, Philadelphia, USA). Salivary lactoferrin and lysozyme were analysed using commercially available ELISA kits (Calbiochem, USA and Biomedical Technologies, USA, respectively) with 500X dilution.
Saliva samples were also assayed for cathelicidin concentration using a commercially available ELISA kit (Hycult Biotech, Uden, The Netherlands). Secretion rates for each of the salivary AMPs were calculated as the multiple of the saliva flow rate and AMP concentration.
All saliva assays were carried out in duplicate. The intra-assay CVs for all the assays were <4% across a working range of 2.5-600 mg/L for SIgA, 1.6-100 g/L for lactoferrin, 0.78-50 g/L for lysozyme and 0.1-100 g/L for cathelicidin.
Statistical analysis
The Shapiro-Wilk test was used to determine if data sets were normally distributed. 
Results
Adherence to the study Thirty nine participants (vitamin D 3 : n=20; placebo: n=19) completed the study and provided sufficient blood for routine haematology and analysis of 25(OH)D and cathelicidin concentrations on 2 occasions and sufficient saliva for analysis of AMPs on all 3 occasions.
Reasons for dropout were given as foreign travel (N=3), injury (N=6) or due to undisclosed reasons (N=2).
Baseline characteristics and physical activity levels
There were no significant differences in baseline anthropometrics or haematological variables between the vitamin D 3 and placebo groups ( (Figure 2a and 2b) . Salivary lysozyme secretion rate increased over time in both groups (time, P=0.002; two-way ANOVA) but lactoferrin secretion rate was unaltered (Figure 2c and 2d). , 2013; He et al., 2013; Owens et al., 2014) . This is most likely due to insufficient ultraviolet radiation of appropriate wavelength (290-315 nm) between
Discussion
November and March in the UK to produce vitamin D in the skin (Webb & Holick, 1988) .
In the present study the resting salivary SIgA and cathelicidin secretion rates significantly Data are shown as the mean ± SD or the median and interquartile range as appropriate. P values are from unpaired t tests apart from IPAQ training load where the Mann-Whitney U test for nonparametric data was used. 
